MedGenome appoints Dr Amit Kakar as chairman in September 2024

On September 11, 2024, MedGenome announced the appointment of Dr. Amit Kakar as the new Chairman of its Board, effective immediately. Dr. Kakar succeeds Dr. Felix Olale, who completed a two-year term and will now focus on expanding MedGenome's business in the US and North America. Dr. Kakar has been a board member since 2022 and is currently the Managing Partner and Head of Asia at Novo Holdings, a prominent life sciences investment firm. With over three decades of experience in healthcare investing and management, Dr. Kakar's leadership is expected to provide strategic direction for MedGenome's growth. His previous roles include significant positions at Avenue Capital and GE Healthcare, where he gained extensive knowledge of the healthcare sector across various regions. His expertise will be crucial as MedGenome aims to enhance its genomic research and diagnostics solutions. Mahesh Pratapneni, Group CEO & Co-founder of MedGenome, expressed confidence in Dr. Kakar's ability to guide the company through its expansion plans. He acknowledged Dr. Kakar's contributions as a board member and emphasized the importance of his industry connections and knowledge in executing the company's long-term strategy. The transition in leadership reflects MedGenome's commitment to strong governance and its mission to improve global health. MedGenome has established itself as a leader in genomics-driven diagnostics, having sequenced over 350,000 exomes and genomes and built a vast network of healthcare providers. The company is dedicated to providing data-driven insights into complex diseases, which is essential for advancing precision medicine and improving healthcare outcomes worldwide.